Table 3.
Model estimates of cost-effectiveness analyses associated with infant and maternal immunisation programs as standalone prevention strategies from healthcare and societal perspectives at the WTP of $50,000 per QALY gained using sigmoidal vaccine efficacy profiles.
| Prevention strategy | Maximum PPD, $ | Incremental costs, $ (95% CI) | QALYs gained (95% CI) | ICER, $/QALY (95% CI) | Budget Impact per 100,000 population, $ |
|---|---|---|---|---|---|
| Healthcare perspective | |||||
| L1 | 615 | 1199 (−380 to 2700) | 0.024 (0.018–0.032) | 49,577 (−14,712 to 125,242) | 1225 |
| L2 | 375 | 1648 (−105 to 3392) | 0.036 (0.028–0.045) | 45,924 (−2959 to 103,322) | 1668 |
| L3 | 300 | 3235 (−163 to 6588) | 0.094 (0.082–0.107) | 34,331 (−1682 to 72,362) | 3303 |
| L4 | 215 | 467 (−3878 to 4708) | 0.111 (0.099–0.124) | 4200 (−34,697 to 43,384) | 503 |
| MI | 160 | 4501 (764–8262) | 0.109 (0.096–0.123) | 41,321 (6800 to 78,174) | 4546 |
| Societal perspective | |||||
| L1 | 705 | 1153 (−453 to 2725) | 0.024 (0.018–0.032) | 47,467 (−18,071 to 128,490) | 4606 |
| L2 | 455 | 1779 (−119 to 3608) | 0.036 (0.028–0.045) | 49,618 (−3025 to 110,691) | 9976 |
| L3 | 385 | 2705 (−1342 to 6703) | 0.094 (0.082–0.107) | 28,634 (−13,811 to 73,395) | 52,738 |
| L4 | 290 | 5195 (68–10,285) | 0.111 (0.099–0.124) | 46,749 (597–95,262) | 83,978 |
| MI | 200 | 2816 (−1495 to 7037) | 0.109 (0.096–0.123) | 25,815 (−13,217 to 66,816) | 49,066 |
All strategies were compared to the baseline with no intervention.